Recommendations for neonatal surfactant therapy;Des recommandations pour le traitement néonatal par surfactant exogène

Paediatrics and Child Health

Volumn 10, Issue 2, 2005, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

SURFACTANT; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT TA;

BRADYCARDIA; CLINICAL TRIAL; DOSE RESPONSE; EVIDENCE BASED MEDICINE; HUMAN; HYPOXEMIA; PRACTICE GUIDELINE; RESPIRATORY DISTRESS SYNDROME; REVIEW; SYSTEMATIC REVIEW; TREATMENT INDICATION;

EID: 16444368246     PISSN: 12057088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959;97:517-23.
2. Robillard E, Alarie Y, Dagenais-Perusse P, Baril E, Guilbeault A. Microaerosol administration of synthetic dipalmitoyl lecithin in the respiratory distress syndrome: A preliminary report. CMAJ 1964;90:55-7.
3. Chu J, Clements JA, Cotton EK, et al. Neonatal pulmonary ischemia: Clinical and physiologic studies. Pediatrics 1967;40(Suppl):709-82.
4. The Cochrane Library. Oxford: Update Software, 2003.
5. Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Chichester: John Wiley & Sons. Ltd.
6. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Chichester: John Wiley & Sons, Ltd.
7. Soll RF. Prophylactic natural surfactant extract for preventing morbidity and mortality in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Chichester, UK: John Wiley & Sons, Ltd.
8. Halliday HL. Overview of clinical trials comparing natural and synthetic surfactants. Biol Neonate 1995;67(Suppl 1):32-47.
9. Halliday, HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. Drugs 1996;51:226-37.
10. Soll RF, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Chichester, UK: John Wiley & Sons, Ltd.
11. Robertson B, Halliday HL. Principles of surfactant replacement. Biochim Biophys Acta 1998;1408:346-61.
12. Kattwinkel J. Surfactant: Evolving issues. Clin Perinatol 1998;25:17-32.
13. Rodriguez RJ, Martin RJ. Exogenous surfactant therapy in newborns. Respir Care Clin N Am 1999;5:595-616.
14. Backhouse ME, Mauskopf JA, Jones D, et al. Economic outcomes of colfosceril palmitate rescue therapy in infants weighing 1250g or more with respiratory distress syndrome: Results from a randomised trial. Pharmacoeconomics 1994;6:358-69.
15. The Victorian Infant Collaborative Study Group. Economic outcome for intensive care of infants of birthweight 500-999 g born in Victoria in the post surfactant era. J Paediatr Child Health 1997;33:202-8.
16. Doyle LW, Davis P, Dharmalingam A, Bowman E. Assisted ventilation and survival of extremely low birthweight infants. J Paediatr Child Health 1996;32:138-42.
17. Phibbs CS, Phibbs RH, Wakeley A, Schlueter MA, Sniderman S, Tooley WH. Cost effects of surfactant therapy for neonatal respiratory distress syndrome. J Pediatr 1993;123:953-62.
18. Soll RF, Jacobs J, Pashko S, Thomas R. Cost effectiveness of beractant in the prevention of respiratory distress syndrome. Pharmacoeconomics 1993;4:278-86.
19. Bryson HM, Whittington R. Colfosceril palmitate. A pharmiicoeconomic evaluation of a synthetic surfactant preparation (Exosurf Neonatal) in infants with respiratory distress syndrome. Pharmacoeconomics 1994;6:563-77.
20. Dargaville PA, South M, McDougall PN. Surfactant and surfactant inhibitors in meconium aspiration syndrome. J Pediatr 2001;138:113-5.
21. Dargaville PA, Morley CJ. Overcoming surfactant inhibition with polymers. Acta Paediatr 2000;89:1397-400,
22. Tashiro K, Kobayashi T, Robertson B. Dextran reduces surfactant inhibition by meconium. Acta Paediatr 2000;89:1439-45.
23. Findlay RD, Taeusch HW, Walther FJ. Surfactant replacement therapy for meconium aspiration syndromes. Pediatrics 1996;97:48-52.
24. Lotze A, Mitchell BR, Bulas DI, Zola EM, Shalwitz RA, Gunkel JH. Multicenter study of surfactant (Beractant) use in the treatment of term infants with severe respiratory failure. J Pediatr 1998;132:40-7.
25. Soll RF, Dargaville P. Surfactant for meconium aspiration syndrome in full term infants (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Chichester, UK: John Wiley & Sons, Ltd.
26. Wiswell TE, Knight GR, Finer NN, et al. A multicenter, randomized, controlled trial comparing Surfaxin (Lucinactant) lavage with standard care for treatment of meconium aspiration syndrome. Pediatrics 2002;109:1081-7.
27. Herting E, Gefeller O, Land M, van Sonderen L, Harms K, Robertson B. Surfactant treatment of neonates with respiratory failure and group B streptococcal infection. Members of the Collaborative European Multicenter Study Group. Pediatrics 2000;106:957-64.
28. Auten RL, Notter RH, Kendig JW, Davis JM, Shapiro DL. Surfactant treatment of full-term newborns with respiratory failure. Pediatrics 1991;87;101.
29. Fetter WP, Baerts W, Bos AP, van Lingen RA. Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis. Acta Paediatr 1995;84:14-6.
30. Raju TN, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: A metaanalysis. J Pediatr 1993;123:603-10.
31. Seeger W, Grube C, Gunther A, Schmidt R. Surfactant inhibition by plasma proteins: Differential sensitivity of various surfactant preparations. Eur Respir J 1993;6:971-7.
32. Johnson AH, Peacock JL, Greenough A, et al. High-frequency oscillatory ventilation for the prevention of chronic lung disease of prematurity. N Engl J Med 2002;347:633-42.
33. Pandit PB, Dunn MS, Colucci EA. Surfactant therapy in neonates with respiratory deterioration due to pulmonary hemorrhage. Pediatrics 1995;95:32-6.
34. Bos AP, Tibboel D, Hazebroek FW, Molenaar JC, Lachmann B, Gommers D. Surfactant replacement therapy in high-risk congenital diaphragmatic hernia. Lancet 1991;338:1279.
35. Glick PL, Leach CL, Besner GE, et al. Pathophysiology of congenital diaphragmatic hernia III: Exogenous surfactant therapy for the high-risk neonate with CDH. J Pediatr Surg 1992;27:866-9.
36. Hentschel R, Jorch G. Acute side effects of surfactant treatment. J Perinat Med 2002;30:143-8.
37. Long W, Corbet A, Cotton R, et al. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group. N Engl J Med 1991;325:1696-703.
38. Pappin A, Shenker N, Hack M, Redline RW. Extensive intraalveolar pulmonary hemorrhage in infants dying after surfactant therapy. J Pediatr 1994;124:621-6.
39. Thornton CM, Halliday HL, O'Hara MD. Surfactant replacement therapy in preterm neonates: A comparison of postmortem pulmonary histology in treated and untreated infants. Pediatr Pathol 1994;14:945-53.
40. Tod P, Buonocore G, Rinaldi G, Catella AM, Bracci R. Pulmonary pathology in surfactant-treated preterm infants with respiratory distress syndrome: An autopsy study. Biol Neonate 1996;70:21-8.
41. Baraldi E, Pettenazzo A, Filippone M, Magagnin GP, Saia OS, Zacchello F. Rapid improvement of static compliance after surfactant treatment in preterm infants with respiratory distress syndrome. Pediatr Pulmonol 1993;15:157-62.
42. Dimitriou G, Greenough A, Laubscher B. Appropriate positive end expiratory pressure level in surfactant-treated preterm infants. Eur J Paediatr 1999;158:888-91.
43. Couser RJ, Ferrara TB, Ebert J, Hoekstra RE, Fangman JJ. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease. J Pediatr 1990;116:119-24.
44. Chida S, Phelps DS, Soll RF, Taeusch HW. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 1991;88:84-9.
45. Bartmann P, Bamberger U, Pohlandt F, Gortner L. Immunogenicity and immunomodulatory activity of bovine surfactant (SF-RI 1). Acta Paediatr 1992;81:383-8.
46. Bambang Oetomo S, Bos AF, de Lei L, et al. Immune response after surfactant treatment of newborn infants with respiratory distress syndrome. Biol Neonate 1993;64:341-5.
47. Strayer DS, Merritt TA, Hallman M. Surfactant replacement: Immunological considerations. Eur Respir J Suppl 1989;3:91S-6S.
48. Merritt TA, Strayer DS, Hallman M, Spragg RD, Wozniak P. Immunologic consequences of exogenous surfactant administration. Semin Perinatol 1989;12:221-30.
49. Survanta Multidose Study Group. Two year follow-up of infants treated for neonatal respiratory distress syndrome with bovine surfactant. J Pediatr 1994;124:962-7.
50. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Chichester, UK: John Wiley & Sons, Ltd.
51. Kendig JW, Ryan RM, Sinkin RA, et al. Comparison of two strategies for surfactant prophylaxis in very premature infants: A multicenter randomized trial. Pediatrics 1998;101;1006-12.
52. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant - the judgment of OSIRIS. Lancet 1992;340:1363-9.
53. Hentschel R, Brune T, Franke N, Harms E, Jorch G. Sequential changes in compliance and resistance after bolus administration or slow infusion of surfactant in preterm infants. Intensive Care Med 2002;28:622-8.
54. Konishi M, Fujiwara T, Naito T, et al. Surfactant replacement therapy in neonatal respiratory distress syndrome. A multi-centre, randomized clinical trial: Comparison of high- versus low-dose of surfactant TA. Eur J Pediatr 1988;147:20-5.
55. Halliday HL, Tarnow-Mordi WO, Corcoran JD, Patterson CC. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial). Arch Dis Child 1993;69:276-80.
56. Soll RF. Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome (Cochrane Review). In: The Cochrane Library, Issue 4, 2004. Chichester, UK: John Wiley & Sons, Ltd.
57. Dunn MS, Shennan AT, Possmayer F. Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome. Pediatrics 1990;86:564-71.
58. Speer CP, Robertson B, Curstedt T, et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: Single versus multiple doses of Curosurf. Pediatrics 1992;89:13-20.
59. Corbet A, Gerdes J, Long W, et al. Double-blind, randomized trial of one versus three prophylactic doses of synthetic surfactant in 826 neonates weighing 700 to 1100 grams: Effects on mortality rate. American Exosurf Neonatal Study Groups I and IIa. J Pediatt 1995;126:969-78.
60. Kattwinkel J, Bloom BT, Delmore P, et al. High-versus low-threshold surfactant retreatment for neonatal respiratory distress syndrome. Pediatrics 2000;106:282-8.
61. Figueras-Aloy J, Quero J, Carbonell-Estrany X, et al. Early administration of the second dose of surfactant (beractant) in the treatment of severe hyaline membrane disease. Acta Paediatr 2001;90:296-301.
62. Verder H, Albertsen P, Ebbesen F, et al. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation. Pediatrics 1999;103:E24.
63. Tooley J, Dyke M. Randomized study of nasal continuous positive airway pressure in the preterm infant with respiratory distress syndrome. Acta Paediatr 2003;92:1170-4.
64. Crane J, Armson A, Brunner M, et al, for the Executive Committee of the Society of Obstetricians and Gynaecologists of Canada. Antenatal corticosteroid therapy for fetal maturation. J Obstec Gynaecol Can 2003;25:45-52.
65. Chien LY, Ohlsson A, Seshia MM, Boulton J, Sankaran K, Lee SK, for the Canadian Neonatal Network. Variations in antenatal corticosteroid therapy: A persistent problem despite 30 years of evidence. Obstet Gynecol 2002;99:401-8.
66. Farrell EE, Silver RK, Kimberlin LV, Wolf ES, Dusik JM. Impact of antenatal dexamethasone administration on respiratory distress syndrome in surfactant treated infants. Am J Obstet Gynecol 1989;161:628-33.
67. Kari MA, Hallman M, Eronen M, et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: A randomized placebo-controlled multicenter study. Pediatr 1994;93:730-6.
68. Silver RK, Vyskocil C, Solomon SL, Ragin A, Neerhof MG, Farrell EE. Randomized trial of antenatal dexamethasone in surfactant-treated infants delivered before 30 weeks' gestation. Obstet Gynecol 1996;87:683-91.
69. Costakos D, Allen D, Krauss A, et al. Surfactant therapy prior to interhospital transport of preterm infants. Am J Perinatol 1996;13:309-16.
70. Mildenhall LF, Pavuluri NN, Bowman ED. Safety of synthetic surfactant use before preterm newborn transport. J Paediatr Child Health 1999;35:530-5.
71. Chien LY, Whyte R, Aziz K, Thiessen P, Matthew D, Lee SK, for the Canadian Neonatal Network. Improved outcome of preterm infants when delivered in tertiary care centers. Obstet Gynecol 2001;98:247-52.